A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia

Abstract Hydroxyurea is an antimetabolite drug that induces fetal haemoglobin in sickle cell disease. However, its clinical usefulness in β-thalassaemia is unproven. We conducted a randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of hydroxyurea in trans...

Full description

Bibliographic Details
Main Authors: Nirmani Yasara, Nethmi Wickramarathne, Chamila Mettananda, Ishari Silva, Nizri Hameed, Kumari Attanayaka, Rexan Rodrigo, Nirmani Wickramasinghe, Lakshman Perera, Aresha Manamperi, Anuja Premawardhena, Sachith Mettananda
Format: Article
Language:English
Published: Nature Portfolio 2022-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-06774-8

Internet

https://doi.org/10.1038/s41598-022-06774-8

Similar Items